Pharma channel feed

Mar­ket­ingRx roundup: Pfiz­er talks about its ‘Char­lie’ AI mar­ket­ing bot; Gilead pledges $12M for HIV pre­ven­tion

Last year
Marketing

Roche is 'e­val­u­at­ing po­ten­tial op­tion­s' for IPF drug Es­bri­et as gener­ics gain trac­tion

Last year

No­vo Nordisk inks pact for dis­cov­ery of 'mol­e­c­u­lar glues' in deal worth as much as $1.46B

Last year
Deals

Rock­et Phar­ma to light up build­ings again for Rare Dis­ease Day as it awaits first FDA de­ci­sion

Last year
Marketing

FDA of­fi­cials, drug de­vel­op­ers dis­cuss how to stream­line safe­ty mon­i­tor­ing for bi­o­log­ics

Last year
FDA+

Fail­ure, faith and $8 bil­lion: How Lil­ly's amy­loid con­vic­tion brought it to the brink of Alzheimer's ap­proval

Last year
In Focus

Col­orado be­gins process to po­ten­tial­ly set pay­ment lim­it on Am­gen's arthri­tis drug En­brel

Last year

VML Health taps cre­ative lead­er­ship in wake of Wun­der­man and VM­LY&R merg­er

Last year
Marketing

New York AG calls for 'more strin­gen­t' Sin­gu­lair safe­ty warn­ings

Last year
FDA+

J&J to close Cal­i­for­nia R&D fa­cil­i­ty with plans to open new 'in­no­va­tion cen­ter'

Last year
R&D

Gilead bid against it­self in $4.3B deal for CymaBay, fil­ing shows

Last year
Deals

Te­va and Alvotech's in­ter­change­able Hu­mi­ra biosim­i­lar joins the par­ty

Last year
FDA+

Bi­par­ti­san group of law­mak­ers op­pos­es Biden's plan to use 'march-in' to low­er drug prices

Last year
Law

Gilead set­tles with Mary­land dis­trib­u­tor over al­leged coun­ter­feit HIV drugs

Last year
Law

Pfiz­er and No­var­tis chiefs lead phar­ma's CEO in­flu­encers on so­cial me­dia, analy­sis finds

Last year
Marketing

FDA de­clines to is­sue fines for non­com­pli­ant tri­al re­port­ing

Last year
FDA+

Bio­Mar­in's Roc­ta­vian, once fore­cast to sell $50M to $150M last year, on­ly pulls in a frac­tion of that

Last year
Cell/Gene Tx

Am­gen wants in on obe­si­ty. But it's still work­ing on rare dis­ease, too

Last year
R&D

Organon ex­pands 'Her Plan is Her Pow­er' re­pro­duc­tive health ini­tia­tive

Last year
Marketing

US prices of some pso­ri­a­sis drugs need to be low­ered to match ben­e­fits, new study says

Last year

Mod­er­na wants an ac­cel­er­at­ed ap­proval for its can­cer vac­cine — but it's wait­ing on three things

Last year
R&D

House Dems seek brief­in­gs with Pfiz­er, San­doz and Te­va on on­go­ing drug short­ages

Last year
FDA+

Eli Lil­ly backs women’s health group­s' cam­paign to spur obe­si­ty treat­ment cov­er­age

Last year
Marketing

Amy­lyx’s ALS drug tastes bit­ter. What would make it bet­ter? More patent life

Last year
R&D
First page Previous page 71727374757677 Next page Last page
A service from the Financial Times